

From: Teva Pharmaceuticals USA, Inc. <TevaPharmaceuticalsUSA@mktg.teva-pharm.com>
Sent: Wednesday, August 14, 2019 1:49 PM
To: Kevin Galownia
Subject: Teva Introduces a Generic of Doryx® (doxycycline hyclate delayed-release tablets) [MARKETING]



TevAlert

New Product Notification

Teva Announces the Introduction of:

Doxycycline Hyclate Delayed-Release Tablets, USP

- AB rated to Doryx®* (doxycycline hyclate delayed-release tablets)
- Please see accompanying full [Prescribing Information](#)

Strength	Size	NDC	SWP [†]	WAC [‡]
50 mg	120 Tablets/Bottle	00591-4550-22	\$1,620.85	\$1,134.60
200 mg	60 Tablets/Bottle	00591-4575-60	\$3,000.73	\$2,100.51

Additional information about this product:

FDA Approval Letter >	HDA Forms >	Prescribing Information >	Labels >
SDS >	ID Photos >	Barcodes >	

For additional information on this or other Teva products, or to place an order, contact your Customer Service Representative at 800.545.8800.

Thank you for your continued support of Teva products.

*Doryx[®] is a registered trademark of Mayne Pharma.

† Suggested Wholesale Price (SWP) does not reflect the actual cost or charge to the pharmacy, wholesaler or customer.

†† Wholesale acquisition cost (WAC) means the manufacturer's list price for the drug to wholesalers or direct purchasers, not including prompt pay or other discounts, rebates, or reductions in price.

To the extent that the customer stated above receives discounts, rebates, incentives or any other price reductions (collectively, "**Price Reductions**") from Teva as a result of purchases made under the agreement between the parties, Teva will fully and accurately document and report such Price Reductions on any invoices, coupons, statements or documents exchanged between Teva and the customer. Customer hereby acknowledges that it may have an obligation to report such Price Reductions to federal or state health care programs pursuant to U.S.C. §1320a-7b(b)(3)(A), the regulations promulgated thereunder, and/or similar laws.

The Parties hereby certify that they shall not violate the federal Anti-Kickback Statute, 42 U.S.C. §1320a-7b(b), in the performance of this Agreement. All Teva employees and contractors will comply with Teva's Compliance Program, including its Code of Conduct and Anti-kickback Statute Policy, which are available at www.tevausea.com/ourimpact/article-pages/Compliance/.

Teva Pharmaceuticals

400 Interpace Pkwy #3, Parsippany, NJ 07054 | tevausea.com

